Table 2.
Primary outcome analysis of PBVC at 96 weeks, intention-to-treat population
| Normalised brain volume at baseline (mL) | PBVC at 96 weeks* | Adjusted mean difference in PBVC vs placebo (95% CI)† | p value† | |
|---|---|---|---|---|
| Amiloride (n=99) | 1426·9 (82·4) | −1·3% (1·0) | 0·0% (−0·4 to 0·5) | 0·99 |
| Fluoxetine (n=96) | 1414·9 (79·9) | −1·4% (1·5) | −0·1% (−0·5 to 0·3) | 0·86 |
| Riluzole (n=99) | 1416·0 (75·0) | −1·4% (1·5) | −0·1% (−0·6 to 0·3) | 0·77 |
| Placebo (n=99) | 1428·8 (91·5) | −1·3% (1·1) | .. | .. |
Data are mean (SD) unless otherwise stated. PBVC=percentage brain volume change.
*
Negative values indicate reductions in brain volume.
†
Adjusted for minimisation variables (age, sex, study centre, and EDSS score at randomisation) and baseline normalised brain volume, and accounted for multiple testing versus a common control group using Dunnett's method.